

NeuralGlider®

Precision Brain Access & Deep Brain Therapy Delivery Platform



THE CHALLENGE

Every brain therapy requires precise brain access.

- More than 10M Americans suffer from neurological disorders, including Parkinson's, Alzheimer's, epilepsy, and depression. Better therapies are needed.
- Existing and emerging therapies depend on **precisely reaching the intended target within the brain, while minimizing trauma to delicate brain tissue.**
- Current and future stereotactic and robotic systems line up the insertion path precisely, based on imaging the patient's brain, but devices still need to stay on the trajectory while navigating the many layers in the brain to reach the target.
- Precision remains a challenge. Wu et al. reported that approximately 80% of DBS lead placements exhibit measurable bending, which can compromise targeting accuracy, therapeutic outcomes, and/or require revision surgeries.
- Deflection and miss rates are an even greater challenge as devices become smaller, more flexible and more sophisticated.

THE SOLUTION — NEURALGLIDER®

Precise brain delivery improves therapy outcomes.

NeuralGlider® uses electronically controlled micro-motion to help thin probes, cannulas, and BCIs transition smoothly through different tissue layers with less buckling, deflection, insertion force, and tissue deformation. It fits existing neurosurgical workflows and complements navigation, robotics, and therapy-delivery systems. It has been validated in 41+ global brain research (preclinical) labs resulting in 44+ peer-reviewed citations and \$500K+ in early preclinical sales.

86%
less insertion
force

70–80%
less dimpling

17% → 75%
increased
success rate

WHY NOW

Brain therapeutics are here. Precision access has arrived.

Four markets are converging on the same bottleneck: neuromodulation, brain-computer interfaces (BCI), CNS gene therapy, and longevity therapeutics.

NeuralGlider® keeps the device on target in all four of these fields.

We are discussing licensing and integration opportunities across neurotechnology ecosystems with both established and new companies and therapies.

TEAM

Proven leadership to execute the 5-year plan.

13 team members · 12 medical advisors · 5 board members · 1 neuro-company exit · 50+ FDA engagements · 9 FDA 510(k) clearances · \$50M non-dilutive capital awarded · 20,000 sq. ft. ISO 13485-certified, FDA-registered facility · In-house regulatory and manufacturing expertise · ~97% U.S. supply chain.

FINANCIAL TRAJECTORY

Projected revenue with profitability in 2028.

\$2.8M	\$35M	\$47M	\$60M	2028 increase driven by:
2027	2028	2029	2030	• First license • Initial clinical sales

INVESTMENT SUMMARY

NeuralGlider® is the precision brain access and deep brain therapy delivery platform designed to solve precision delivery with less tissue damage.

Built and validated with \$18M+ in non-dilutive funding over 10+ years, the platform is entering clinical translation with projected recurring clinical product revenue and multiple OEM and field-of-use licensing pathways.

Hit the brain target the first time.



WHY INVEST

- Validated platform, not a concept
- \$500K+ early preclinical sales
- Licensing model with recurring profitable clinical component sales
- Multiple shots on goal strategy

USE OF PROCEEDS

- First-in-human studies
- FDA 510(k) submission and clearance
- Commercial product readiness
- Establish use with KOLs

DEAL TERMS

- \$10M Series A
- \$25M pre-money
- Participating preferred shares + warrants
- \$25K minimum investment
- Keiretsu Forum Mid-Atlantic term sheet
- 5–6 year planned strategic exit

REACH OUT TO JOIN OUR VISION

Maureen L. Mulvihill, Ph.D.
President & CEO
maureen@actuatedmedical.com
814 355 0003 x100

Series A
Information

